Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal - PubMed (original) (raw)
Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal
Alexandre Surget et al. Biol Psychiatry. 2008.
Abstract
Background: Depression and anxiety disorders have been linked to dysfunction of the hypothalamo-pituitary-adrenal (HPA) axis and structural changes within the hippocampus. Unpredictable chronic mild stress (UCMS) can recapitulate these effects in a mouse model, and UCMS-induced changes, including downregulation of hippocampal neurogenesis, can be reversed by antidepressant (AD) treatment. We investigated causality between changes in hippocampal neurogenesis and the effects of both chronic stress and chronic ADs.
Methods: Mice were treated with either a sham procedure or focal hippocampal irradiation to disrupt cell proliferation before being confronted with 5 weeks of UCMS. From the third week onward, we administered monoaminergic ADs (imipramine, fluoxetine), the corticotropin-releasing factor 1 (CRF(1)) antagonist SSR125543, or the vasopressin 1b (V(1b)) antagonist SSR149415 daily. The effects of UCMS regimen, AD treatments, and irradiation were assessed by physical measures (coat state, weight), behavioral testing (Splash test, Novelty-Suppressed feeding test, locomotor activity), and hippocampal BrdU labeling.
Results: Our results show that elimination of hippocampal neurogenesis has no effect on animals' sensitivity to UCMS in several behavioral assays, suggesting that reduced neurogenesis is not a cause of stress-related behavioral deficits. Second, we present evidence for both neurogenesis-dependent and -independent mechanisms for the reversal of stress-induced behaviors by AD drugs. Specifically, loss of neurogenesis completely blocked the effects of monoaminergic ADs (imipramine, fluoxetine) but did not prevent most effects of the CRF(1) and the V(1b) antagonists.
Conclusions: Hippocampal neurogenesis might thus be used by the monoaminergic ADs to counteract the effects of stress, whereas similar effects could be achieved by directly targeting the HPA axis and related neuropeptides.
Similar articles
- Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression.
Alonso R, Griebel G, Pavone G, Stemmelin J, Le Fur G, Soubrié P. Alonso R, et al. Mol Psychiatry. 2004 Mar;9(3):278-86, 224. doi: 10.1038/sj.mp.4001464. Mol Psychiatry. 2004. PMID: 14699428 - Multifaceted strain-specific effects in a mouse model of depression and of antidepressant reversal.
Ibarguen-Vargas Y, Surget A, Touma C, Palme R, Belzung C. Ibarguen-Vargas Y, et al. Psychoneuroendocrinology. 2008 Nov;33(10):1357-68. doi: 10.1016/j.psyneuen.2008.07.010. Epub 2008 Sep 13. Psychoneuroendocrinology. 2008. PMID: 18790573 - Differential environmental regulation of neurogenesis along the septo-temporal axis of the hippocampus.
Tanti A, Rainer Q, Minier F, Surget A, Belzung C. Tanti A, et al. Neuropharmacology. 2012 Sep;63(3):374-84. doi: 10.1016/j.neuropharm.2012.04.022. Epub 2012 Apr 28. Neuropharmacology. 2012. PMID: 22561281 - Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test.
Dulawa SC, Hen R. Dulawa SC, et al. Neurosci Biobehav Rev. 2005;29(4-5):771-83. doi: 10.1016/j.neubiorev.2005.03.017. Neurosci Biobehav Rev. 2005. PMID: 15890403 Review. - Adult hippocampal neurogenesis in depression.
Sahay A, Hen R. Sahay A, et al. Nat Neurosci. 2007 Sep;10(9):1110-5. doi: 10.1038/nn1969. Nat Neurosci. 2007. PMID: 17726477 Review.
Cited by
- BMP Antagonist Gremlin 2 Regulates Hippocampal Neurogenesis and Is Associated with Seizure Susceptibility and Anxiety.
Frazer NB, Kaas GA, Firmin CG, Gamazon ER, Hatzopoulos AK. Frazer NB, et al. eNeuro. 2024 Oct 17;11(10):ENEURO.0213-23.2024. doi: 10.1523/ENEURO.0213-23.2024. Print 2024 Oct. eNeuro. 2024. PMID: 39349059 Free PMC article. - Astrocytic RARγ mediates hippocampal astrocytosis and neurogenesis deficits in chronic retinoic acid-induced depression.
Huang H, Lu W, Luo R, Zeng Y, Zhang Y, Su X, Zhang X, Tian B, Wang X. Huang H, et al. Neuropsychopharmacology. 2024 Sep 6. doi: 10.1038/s41386-024-01983-3. Online ahead of print. Neuropsychopharmacology. 2024. PMID: 39242924 - TAARs as Novel Therapeutic Targets for the Treatment of Depression: A Narrative Review of the Interconnection with Monoamines and Adult Neurogenesis.
Shemiakova TS, Efimova EV, Gainetdinov RR. Shemiakova TS, et al. Biomedicines. 2024 Jun 6;12(6):1263. doi: 10.3390/biomedicines12061263. Biomedicines. 2024. PMID: 38927470 Free PMC article. Review. - Aerobic exercise improves depressive symptoms in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.
Loughlin H, Jackson J, Looman C, Starll A, Goldman J, Shan Z, Yu C. Loughlin H, et al. IBRO Neurosci Rep. 2024 Mar 12;16:468-475. doi: 10.1016/j.ibneur.2024.03.004. eCollection 2024 Jun. IBRO Neurosci Rep. 2024. PMID: 38560366 Free PMC article. - Cannabinoid type 2 receptor inhibition enhances the antidepressant and proneurogenic effects of physical exercise after chronic stress.
Rodrigues RS, Moreira JB, Mateus JM, Barateiro A, Paulo SL, Vaz SH, Lourenço DM, Ribeiro FF, Soares R, Loureiro-Campos E, Bielefeld P, Sebastião AM, Fernandes A, Pinto L, Fitzsimons CP, Xapelli S. Rodrigues RS, et al. Transl Psychiatry. 2024 Mar 30;14(1):170. doi: 10.1038/s41398-024-02877-0. Transl Psychiatry. 2024. PMID: 38555299 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical